XTLB Stock Summary and Trading Ideas (XTL Biopharmaceuticals Ltd. - American Depositary Shares | NASDAQ:XTLB)

XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.

XTL Biopharmaceuticals Ltd. - American Depositary Shares trades on the NASDAQ stock market under the symbol XTLB.

As of April 29, 2026, XTLB stock price climbed to $3.56 with 98,505,958 million shares trading.

XTLB has a beta of 1.63, meaning it tends to be more sensitive to market movements. XTLB has a correlation of 0.05 to the broad based SPY ETF.

XTLB has a market cap of $33.69 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, XTLB traded as high as $19.96 and as low as $2.12.

XTLB has underperformed the market in the last year with a return of -33.8%, while the SPY ETF gained +30.5%. In the last 3 month period, XTLB fell short of the market, returning +0.2%, while SPY returned +2.6%. However, in the most recent 2 weeks XTLB has outperformed the stock market by returning +45.6%, while SPY returned +2.5%.

XTLB support price is $2.10 and resistance is $2.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XTLB shares will trade within this expected range on the day.